| Previous close | 23.75 |
| Open | 23.69 |
| Bid | 23.42 x 68800 |
| Ask | 23.78 x 1500 |
| Day's range | 23.42 - 23.80 |
| 52-week range | 16.48 - 26.97 |
| Volume | 470,559 |
| Avg. volume | 1,142,153 |
| Market cap | 14.57B |
| Beta | 0.85 |
| PE ratio (TTM) | 28.73 |
| EPS (TTM) | 0.82 |
| Earnings date | 28 Jul 2017 |
| Dividend & yield | 0.54 (1.85%) |
| Ex-dividend date | 2016-12-05 |
| 1y target est | N/A |
- PR Newswire•29 days ago
Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples
BARCELONA, Spain, June 22, 2017 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, and a leader in the development of innovative diagnostic solutions, is expanding its Texas-based Clinical Diagnostics Laboratory menu by launching therapeutic drug monitoring testing services. As the standard of care changes towards individualized patient care in diseases such as inflammatory bowel diseases, the clinicians' demand for monitoring biologic drugs is growing.
- Investor's Business Daily•last month
When 'New' Means A Stock Hasn't Led The Market In A While
Celgene and Grifols are former leaders, but enough time has passed to give them a new shine.
- Zacks•last month
Should Value Investors Consider Grifols (GRFS) Stock Right Now?
Is Grifols a great pick from the value investor's perspective right now? Read on to know more.
